Tallac Therapeutics
PrivateLast Round
Debt
Jul 31, 2023
Total Funding Raised
$67M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Tallac Therapeutics is a biopharmaceutical company that develops antibody-oligonucleotide conjugates to harness innate and adaptive immunity for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tallac Therapeutics Comparables
Compare Tallac Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bolt Biotherapeutics | 81% | |
| ARS Pharmaceuticals | 78% | |
| Canwell Biotech Ltd. | 73% |
Tallac Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Jul 31, 2023 | ||||
| Series A | Dec 1, 2020 |
Key People
Founding team and executive leadership
Tallac Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Matrix | Series A |
| Lightstone Ventures | Series A |
| Morningside Ventures | Series A |
| MPC | Series A |
| Horizon Technology Finance Corporation | Debt |
| venBio | Series A |
| Morningside Group | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 38% MoM, reaching 1.9K.
- May 16, 2026
Monthly visitors increased 194% MoM, reaching 2.4K.
Tallac Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Tallac Therapeutics's valuation, stock price, and market status.
Is Tallac Therapeutics a public or private company?
Tallac Therapeutics is a private company.
What is the current stock price of Tallac Therapeutics?
Tallac Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Tallac Therapeutics worth (valuation)?
Valuation information for Tallac Therapeutics is not publicly available.
Can I buy Tallac Therapeutics stock?
Tallac Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Tallac Therapeutics's last funding round?
Tallac Therapeutics's most recent funding round was Debt on August 2, 2023.
Who are the main investors in Tallac Therapeutics?
Key investors in Tallac Therapeutics include Morningside Ventures, MPCi, Horizon Technology Finance Corporation, venBio, Morningside Group.
Will Tallac Therapeutics IPO soon?
No public IPO plans have been announced for Tallac Therapeutics.
How can I track Tallac Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tallac Therapeutics's secondary market activity and sign up for updates.